Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Taysha Gene Therapies, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.5
15.5
8.33
9.77
Research and development
31.9
132
91.2
56.8
66
86.4
General and administrative
11.1
41.3
37.4
30
29
33.9
Operating expenses
43
173
165
87.9
99.8
120
Operating income
-43
-173
-162
-72.4
-91.5
-110
Interest expense
0.03
1.43
3.8
5
0.1
0.06
Interest income
3.57
6.94
9.22
Other non-operating income
-17
-1.26
-3.57
-39.1
2.16
1.5
Income tax
0
0
0
0
0
Net income
-60
-175
-166
-112
-89.3
-109
EBITDA
-43
-173
-161
-71.1
-90.2
-109
EPS, basic
-3.40
-4.64
-3.78
-0.96
-0.36
-0.34
EPS, diluted
-3.40
-4.64
-3.78
-0.96
-0.36
-0.34
Shares, basic (weighted)
17.7
37.7
44
116
250
320
Shares, diluted (weighted)
17.7
37.7
44
116
250
320
Balance sheet
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
251
149
87.9
144
139
320
Other current assets
0.33
0.86
0.47
0.29
0.31
0.8
Total current assets
258
160
96.4
150
142
325
Property, plant and equipment
0.29
50.6
15
10.8
7.49
6.74
Lease right-of-use assets
10.9
9.58
8.38
9.44
Other non-current assets
1.11
1.32
0.3
0.22
0.18
Total assets
259
214
126
173
160
343
Accounts payable
1.99
21.8
10.9
6.37
3.59
6.28
Accrued liabilities
1.77
7.7
2.52
3.42
5.24
9.43
Deferred revenue
33.6
18.1
9.77
Total current liabilities
7.13
51.7
62.8
36.8
26.2
26.6
Long-term debt
37.2
38
40.5
43.9
50.1
Lease liabilities
20.4
19
17.4
18.2
Other non-current liabilities
0.45
3.74
4.13
1.58
1.31
1.55
Total liabilities
7.58
119
125
97.8
88.8
96.4
Total debt
37.2
38
40.5
43.9
50.1
Paid-in capital
312
331
402
588
678
958
Retained earnings
-61.1
-236
-401
-513
-602
-711
Other comprehensive income
-4.03
-0.19
Shareholders' equity
251
95.4
0.95
74.9
71.5
247
Total equity
251
95.4
0.95
74.9
71.5
247
Total liabilities and equity
259
214
126
173
160
343
Shares outstanding
37.8
38.5
63.2
187
205
285
Cash flow statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-60
-175
-166
-112
-89.3
-109
Depreciation and amortization
0.01
0.49
1.17
1.37
1.25
1.15
Stock-based compensation
3.35
18.2
18
7.91
13.1
13.3
Change in payables
1.96
14.5
-7.8
-2.3
-2.92
-0.15
Cash from operations
-30.7
-117
-88.4
-73
-81.2
-93.1
Capital expenditures
-0.08
-15.3
-20.6
-3.87
-0.37
-0.74
Cash from investing
-9.08
-21.6
-24.9
-7.35
-0.36
-0.6
Stock issued
0.5
1.22
Cash from financing
291
39.1
52.1
136
76.7
275
Net change in cash
251
-99.5
-61.2
56
-4.9
181
Free cash flow
-30.8
-132
-109
-76.9
-81.6
-93.8
Interest paid
0.03
0.64
2.78
4.95
5.28
5.4
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.67 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-2,792.0%
Operating income / revenue.
EBITDA margin
-2,771.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-2,728.0%
Net income / revenue.
FCF margin
-2,417.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,410.0%
Cash from operations / revenue.
Return on equity (ROE)
-38.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.8%
Net income / average total assets.
R&D / revenue
2,245.0%
Research and development expense / revenue.
Stock-based pay / revenue
331.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
6.9%
Capital expenditures / revenue.
D&A / revenue
21.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
17.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
57.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
245.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
538.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-0.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
114.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
39.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
5.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
27.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
93.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
78.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
17.8x
Current assets / current liabilities.
Quick ratio
17.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
17.5x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.13x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
10.5%
Total debt / total assets.
Liabilities / assets
17.7%
Total liabilities / total assets.
Net debt
-$406.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
FCF per share
-$0.36
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.36
Cash from operations / diluted weighted shares.
Book value per share
$1.19
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
277x
Market cap / revenue.
P/B
3.93x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.93x
Market cap / tangible book value, when positive.
EV/Sales
203x
Enterprise value / revenue.
FCF yield
-8.7%
Free cash flow / market cap.
Earnings yield
-9.8%
Net income / market cap (the inverse of P/E).
What was Taysha Gene Therapies, Inc.'s revenue in fiscal 2025?
Taysha Gene Therapies, Inc. reported revenue of $9.8M for fiscal 2025, 17.3% higher than the year before.
Was Taysha Gene Therapies, Inc. profitable in fiscal 2025?
No. It reported a net loss of $109.0M.
How much free cash flow did Taysha Gene Therapies, Inc. generate in fiscal 2025?
Cash from operations of $93.1M minus capital expenditures of $738.0K left free cash flow of -$93.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.